Related Experiment Videos
Pivmecillinam for bacteriuria in pregnancy.
The Journal of Antimicrobial Chemotherapy
|April 1, 1984
Summary
Pivmecillinam effectively treated bacteriuria in pregnant women, with most delivering healthy babies. Long-term low-dose pivmecillinam prevented further infections during pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Bacteriuria in pregnancy is a common condition.
- Untreated bacteriuria can lead to adverse pregnancy outcomes.
- Antibiotic treatment is standard, but optimal regimens require investigation.
Purpose of the Study:
- To evaluate the efficacy of pivmecillinam in treating bacteriuria during pregnancy.
- To assess the effectiveness of low-dose pivmecillinam in preventing recurrent bacteriuria in pregnancy.
Main Methods:
- A cohort of 44 pregnant women with bacteriuria received pivmecillinam.
- Treatment success was assessed based on bacterial clearance.
- A subset of women were randomized to receive either low-dose pivmecillinam or placebo for extended treatment.
Main Results:
- Pivmecillinam achieved a high success rate (87%) in treating bacteriuria in the initial 38 assessed patients.
- Recurrent bacteriuric episodes were significantly lower in the low-dose pivmecillinam group compared to controls.
- Of 41 women followed to term, 39 delivered healthy infants; adverse outcomes were not linked to treatment.
Conclusions:
- Pivmecillinam is an effective treatment for bacteriuria in pregnancy.
- Low-dose, extended pivmecillinam therapy appears beneficial in preventing recurrent urinary tract infections during gestation.
- Pivmecillinam is a safe option for pregnant women, with no treatment-related adverse effects observed in infants.